Vor Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
61.8%projected annual EPS growth
Analyst Coverage
8analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q4 and Full Year 2026 Earnings Release | 25 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Marketable Securities Balance Quarterly491.5MTarget: Sufficient to fund operations into early 2029
UPSTREAM MG Phase 3 Trial Enrollment Progress QuarterlyTarget: Complete enrollment for generalized myasthenia gravis global trial
UPSTREAM SjD Phase 3 Trial Enrollment Progress QuarterlyTarget: Enroll approximately 250 patients with active primary Sjögren's disease
Watch Items
- Topline data readout from the global Phase 3 UPSTREAM MG trial in generalized myasthenia gravisTrigger: First Half of 2027 (1H 2027)Action: Evaluate clinical efficacy (MG-ADL score improvement) and safety profile to prepare for BLA submission
- Enrollment and site activation progress for the global Phase 3 UPSTREAM SjD trial in primary Sjögren's diseaseTrigger: Ongoing enrollment milestones through 2026/2027Action: Monitor clinical trial site activation and patient recruitment rates across the US, Europe, and South America
- R&D and G&A expense trends post-strategic pivotTrigger: Quarterly cash burn rate exceeding projected runway parametersAction: Optimize clinical trial operational costs and manage administrative overhead to preserve cash runway into 2029
Research as of 20 Jun 2026